Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients | Zendy

Michael Trang | Zendy; David C. Griffith | Zendy; Sujata M. Bhavnani | Zendy; J. Loutit | Zendy; Michael N. Dudley | Zendy; Paul G. Ambrose | Zendy; Christopher M. Rubino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

Author(s) -

Michael Trang,

David C. Griffith,

Sujata M. Bhavnani,

J. Loutit,

Michael N. Dudley,

Paul G. Ambrose,

Christopher M. Rubino

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02606-20

Subject(s) - pharmacokinetics , medicine , volume of distribution , nonmem , meropenem , renal function , population , pharmacodynamics , clearance , covariate , urinary system , antibiotics , pharmacology , urology , biology , microbiology and biotechnology , antibiotic resistance , statistics , mathematics , environmental health

Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research